Literature DB >> 11295216

Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells.

T Minko1, P Kopecková, J Kopecek.   

Abstract

The purpose of the study was to examine the role of caspases in signaling pathways of apoptosis induced by free doxorubicin (DOX) and HPMA copolymer-bound DOX (P(GFLG)-DOX) in human ovarian carcinoma cells. Sensitive A2780 and DOX resistant A2780/AD cells were exposed to different doses of drugs within 12, 18, 24 and 36 h. Caspase activity, expression of genes encoding human caspases 1-10, Apaf-1 and bcl-2 proteins and apoptosis were studied. In sensitive cells both free and P(GFLG)-DOX activated caspases 3, 7 and 9. In addition, P(GFLG)-DOX activated caspases 6 and 8. In resistant cells apoptosis induced by free DOX depended on the activation of caspases 2, 7 and 9, while caspase 3 was not involved; this explains the low degree of apoptosis induced by free DOX in resistant cells. P(GFLG)-DOX triggered the additional caspases 3, 6 and 8. A more pronounced degree of caspase activation and apoptosis after the action of P(GFLG)-DOX depended on the inhibition of bcl-2-encoded cellular defensive mechanisms and a more significant activation of Apaf-1. It was concluded that HPMA copolymer-bound DOX induced additional caspase-dependent apoptosis signaling pathways and the degree of the induction was higher, which led to more pronounced apoptosis when compared to free DOX.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295216     DOI: 10.1016/s0168-3659(01)00220-6

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 2.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

3.  A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.

Authors:  Xu Wang; Jun Li; Yuxiang Wang; Lydia Koenig; Ada Gjyrezi; Paraskevi Giannakakou; Edwin H Shin; Mourad Tighiouart; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-07-11       Impact factor: 15.881

4.  Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells.

Authors:  Tamara Minko; Elena V Batrakova; Shu Li; Yili Li; Refika I Pakunlu; Valery Yu Alakhov; Alexander V Kabanov
Journal:  J Control Release       Date:  2005-07-20       Impact factor: 9.776

5.  Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.

Authors:  Refika I Pakunlu; Thomas J Cook; Tamara Minko
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

6.  HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function.

Authors:  Alexander Malugin; Pavla Kopecková; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

7.  Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.

Authors:  Xiaowei Dong; Cynthia A Mattingly; Michael T Tseng; Moo J Cho; Yang Liu; Val R Adams; Russell J Mumper
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

Review 8.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

9.  Targeted proapoptotic LHRH-BH3 peptide.

Authors:  Sonia S Dharap; Tamara Minko
Journal:  Pharm Res       Date:  2003-06       Impact factor: 4.200

10.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.